Neptune Secures Another U.S. Patent
2012年10月1日 - 9:00PM
Neptune Technologies & Bioressources Inc.
("
Neptune") (Nasdaq:NEPT) (TSX:NTB) is proud to
announce that the U.S. Patent & Trademark Office (the
"
USPTO") will tomorrow grant its new patent, US
8,278,351 (the "
Continuation Patent"). The
Continuation Patent claims the benefit of another of Neptune's U.S.
Patents, No. 8,030,348, (the "
Parent") and
contains claims to krill extracts comprising a phospholipid
suitable for human consumption. These new claims cover all of
Neptune's products, including the successful NKO® brand, and a
number of krill oil products currently sold in the U.S. market.
The Continuation Patent, filed about a year ago, was allowed by
the USPTO after a thorough examination which included a review of a
substantial volume of prior art references and other materials,
including the papers from the re-examination requests filed by Aker
Biomarine ASA ("Aker") directed to the Parent and
a related Neptune patent in the U.S., as well as the oppositions
being undertaken on related Neptune patents in Europe and
Australia.
"The granting of the Continuation Patent further reinforces our
position as the pioneer in the krill oil industry and reiterates to
our investors, shareholders, and clients that we are committed to
continuously building and defending our IP and market position, not
only in the United States, but also throughout the world," stated
Henri Harland, President and CEO of Neptune. "We expect that our
competitors will attempt to minimize this achievement. However, the
fact that the USPTO has allowed the Continuation Patent, after
considering all the prior art and evidence submitted by Aker in the
re-examination, is, for us, a clear indication of the strength and
validity of the claims," he added. "Neptune maintains its policy of
enforcing its patents against anyone who infringes," he
concluded.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX) accepts responsibility for the adequacy or accuracy of this
release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain
and forward-looking. The forward-looking statements contained
herein are also subject generally to other risks and uncertainties
that are described from time to time in the Company's reports filed
with the Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 9 2024 まで 10 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 10 2023 まで 10 2024